Rajendra Kumar-Singh, Ph.D. is a Professor of Developmental, Molecular, and Chemical Biology (DMCB) at Tufts University School of Medicine in Boston, MA and a co founder and VP of Hemera Biosciences Inc. His research interests are in the development of therapies for retinal degeneration including age related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. Rajendra obtained his Ph.D. from The University of Dublin, Trinity College in Ireland followed by a postodoctroal fellowship at the University of Michigan in Ann Arbor.
Rajendra then moved to the UCLA School of Medicine as a junior faculty and then as an Assistant Professor at The University of Utah. Rajendra joined Tufts University School of Medicine approximately 10 years ago where he moved through the ranks and is currently a tenured Professor in DMCB, Neuroscience, and Ophthalmology. The focus of Hemera Biosciences Inc. is to develop gene therapy for the dry form of AMD, specifically by targeting the membrane attack complex of complement. Phase I clinical trials are currently ongoing.